Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jazz Tunes Up For Business Development

This article was originally published in The Pink Sheet Daily

Executive Summary

With a highly competitive effective tax rate, half a billion dollars in cash, and access to attractively priced capital, specialty pharma Jazz, itself the subject of takeover rumors, has stepped up its ongoing hunt for late-stage assets.

You may also be interested in...

Jazz’s $1 Billion Buyout Of Gentium Adds To European Hematology Franchise

The $1 billion purchase price is tied to EU-approved Defitelio, an orphan drug to treat a rare hepatic disorder in patients receiving stem-cell transplants. The drug is not approved in the U.S. – an NDA was pulled in 2011 due to FDA concerns about data quality.

Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid

Perrigo is using Elan’s beneficial tax rates to launch its international expansion and the royalty stream from Tysabri to help fund those M&A endeavors, but is not dramatically changing its OTC focus.

Jazz Cools On Women’s Health, Sells Unit To Meda

The sale of an asset portfolio that includes Elsetrin for hot flashes could give Jazz the financial flexibility for another product acquisition.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts